Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation

Transplant International

Volumn 28, Issue 8, 2015, Pages 928-937

  Kamar, Nassim ^a,b,c   Del Bello, Arnaud ^a,b   Belliere, Julie ^a   Rostaing, Lionel ^a,b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

calcineurin inhibitors; kidney transplantation; minimization; mycophenolic acid; withdrawal

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT WITHDRAWAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GRAFT REJECTION;

CALCINEURIN INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; WITHHOLDING TREATMENT;

EID: 84947038984     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12515     Document Type: Review

References (41)

1. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
2. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB,. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
4. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
6. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
7. Klintmalm GB, Feng S, Lake JR, et al,. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant 2014; 14: 1817.
8. Diekmann F,. Immunosuppressive minimization with MTOR inhibitors and belatacept. Transpl Int 2015; 28: 921.
9. McGrath JS, Shehata M,. Chronic allograft nephropathy: Prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transplant Proc 2001; 33: 2193.
10. Weir MR, Ward MT, Blahut SA, et al,. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
11. Weir MR, Blahut S, Drachenburg C, et al,. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379.
12. Suwelack B, Gerhardt U, Hohage H,. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
13. Dudley C, Pohanka E, Riad H, et al,. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466.
14. Stoves J, Newstead CG, Baczkowski AJ, Owens G, Paraoan M, Hammad AQ,. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2113.
15. Frimat L, Cassuto-Viguier E, Charpentier B, et al,. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6: 2725.
16. Frimat L, Cassuto-Viguier E, Provot F, et al,. Long-term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction: REFERENCE Study 3-year follow up. J Transplant 2010; 2010: pii: 402750. doi: 10.1155/2010/402750.
17. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, Ijzermans JN, Weimar W,. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143.
18. Keunecke C, Rothenpieler U, Zanker B, et al,. Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 2000; 32: 6S.
19. Abramowicz D, Manas D, Lao M, et al,. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725.
20. Abramowicz D, Del Carmen Rial M, Vitko S, et al,. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
21. Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D,. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005; 79: 304.
22. Pascual M, Curtis J, Delmonico FL, et al,. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501.
23. Etienne I, Toupance O, Benichou J, et al,. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrol Dial Transplant 2010; 25: 3096.
24. Kamar N, Rostaing L, Cassuto E, et al,. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Clin Nephrol 2012; 77: 126.
25. Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N,. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. Transplantation 2011; 92: 550.
26. Tran HT, Acharya MK, McKay DB, et al,. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000; 11: 1903.
27. Vincenti F, Ramos E, Brattstrom C, et al,. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
28. Grinyo JM, Gil-Vernet S, Cruzado JM, et al,. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003; 16: 820.
29. Arbogast H, Huckelheim H, Schneeberger H, et al,. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial. Clin Transplant 2005; 19: 309.
30. Asberg A, Midtvedt K, Line PD, et al,. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62.
31. Guba M, Rentsch M, Wimmer CD, et al,. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. Transpl Int 2008; 21: 637.
32. Hazzan M, Labalette M, Copin MC, et al,. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509.
33. Hazzan M, Buob D, Labalette M, et al,. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006; 82: 657.
34. Ekberg H, Grinyo J, Nashan B, et al,. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560.
35. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
36. Grinyo JM, Ekberg H, Mamelok RD, et al,. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009; 24: 2269.
37. Frei U, Daloze P, Vitko S, et al,. Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. Clin Transplant 2010; 24: 500.
38. Ekberg H, Bernasconi C, Tedesco-Silva H, et al,. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
39. Moore J, Middleton L, Cockwell P, et al,. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009; 87: 591.
40. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
41. Schnuelle P, van der Heide JH, Tegzess A, et al,. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536.